Table 2.
Analysis of serum sVEGFR-1 levels in SLE by clinical features.
| Clinical features | Positive n (%) | Negative n (%) | Z | P |
|---|---|---|---|---|
| Vasculitis | 10 (16.39) | 51 (83.61) | 1.013 | 0.311 |
| Arthritis | 21 (34.43) | 40 (65.57) | 3.931 | 0.001 |
| Rash | 23 (37.70) | 38 (62.30) | 0.551 | 0.582 |
| Alopecia | 15 (24.59) | 46 (75.41) | 2.311 | 0.021 |
| Fever | 11 (18.03) | 50 (81.97) | 1.163 | 0.245 |
| Hypocomplementemia | 21 (34.43) | 40 (65.57) | 1.199 | 0.230 |
| ds-DNA | 23 (37.70) | 38 (62.30) | 2.188 | 0.029 |
| Thrombocytopenia | 17 (27.87) | 44 (72.13) | 0.434 | 0.664 |
| Hematuria | 19 (31.15) | 42 (68.85) | 2.383 | 0.017 |
| Proteinuria | 31 (50.82) | 30 (49.18) | 1.774 | 0.076 |
| SLEDAI | 38 (62.30) | 23 (37.70) | 3.199 | 0.001 |
sVEGFR-1 soluble vascular endothelial growth factor receptor-1, SLE systemic lupus erythematosus, SLEDAI SLE disease activity index.